Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Longholder99on Aug 21, 2024 5:38pm
211 Views
Post# 36190788

RE:CLARIFICATION NEEDED FROM CO.

RE:CLARIFICATION NEEDED FROM CO.To be clear.  The company has stated that Metformin does activate Rutherin as demonstrated in a preclinical study.  Does activate....not potentially.  Also, Rutherin is not yet FDA approved so it feels like after the 57M share dilution passes us by when that many warrants expire.  The approval of Rutherin will also have been preceded with a list of uses including the subject of the study (NMIBC),  that will add to the seemingly longer and longer list of cancer indications Rutherin can be used off label for.  Compounding the dollar value of this drug upon approval.  A perfect storm in the making.  
<< Previous
Bullboard Posts
Next >>